<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534935</url>
  </required_header>
  <id_info>
    <org_study_id>B1971035</org_study_id>
    <secondary_id>2011-004400-38</secondary_id>
    <nct_id>NCT02534935</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.</brief_title>
  <official_title>A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To &lt;18 Months Or 18 To &lt;24 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the immunogenicity, safety and tolerability of a
      new vaccine that might prevent meningococcal B disease. The study will be conducted in
      healthy toddlers aged between 12 and 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</measure>
    <time_frame>within 7 Days after Vaccination 1</time_frame>
    <description>Local reactions included tenderness at injection site, swelling and redness collected by using an electronic diary (e-diary). Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</measure>
    <time_frame>within 7 Days after Vaccination 2</time_frame>
    <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</measure>
    <time_frame>within 7 Days after Vaccination 3</time_frame>
    <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</measure>
    <time_frame>within 7 Days after Vaccination 1</time_frame>
    <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</measure>
    <time_frame>within 7 Days after Vaccination 2</time_frame>
    <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</measure>
    <time_frame>within 7 Days after Vaccination 3</time_frame>
    <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 1</measure>
    <time_frame>within 30 Days after Vaccination 1</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 2</measure>
    <time_frame>within 30 Days after Vaccination 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 3</measure>
    <time_frame>within 30 Days after Vaccination 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination</measure>
    <time_frame>within 30 Days after any Vaccination</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase</measure>
    <time_frame>From the Vaccination 1 up to 1 month after Vaccination 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Follow up Phase</measure>
    <time_frame>From 1 month after Vaccination 3 up to 6 months after Vaccination 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC)Throughout the Study</measure>
    <time_frame>From Vaccination 1 up to 6 months after Vaccination 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titer Between 12 Months to Less Than (&lt;) 24 Months &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</measure>
    <time_frame>1 Month After Vaccination 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2</measure>
    <time_frame>1 month (Mon) after Vaccination (Vac) 2</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</measure>
    <time_frame>Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</measure>
    <time_frame>Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Meningococcal B Disease</condition>
  <arm_group>
    <arm_group_label>rLP2086 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm stratified by age:
≥12 to &lt;18 months and ≥18 to &lt;24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm stratified by age:
≥12 to &lt;18 months and ≥18 to &lt;24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 vaccine</intervention_name>
    <description>60 mcg or 120mcg at 0, 2 and 6 months</description>
    <arm_group_label>rLP2086 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediatric HAV vaccine</intervention_name>
    <description>0.5-mL dose at months 0 and 6. Normal saline at month 2.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 12 to &lt;15 months or 18 to &lt;24 months during
             sentinel-cohort enrollment, Or,12 to &lt;24 months during expanded-cohort enrollment.

          -  Subjects must have received all vaccinations in the relevant National Immunization
             Program (NIP) for their age group.

          -  Subject is determined to be in good health by medical history, physical examination,
             and judgment of the investigator.

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine
             during Stage 1 of the study.

          -  Contraindication to vaccination with any HAV vaccine or known latex allergy.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  A known or suspected disorder of the immune system that would prevent an immune
             response to the vaccine, such as subjects with congenital or acquired defects in
             B-cell function or those receiving systemic immunosuppressive therapy. Subjects with
             terminal complement deficiency may be included.

          -  History of microbiologically proven disease caused by N meningitidis or Neisseria
             gonorrhoeae.

          -  Significant neurologic disorder or history of seizure (excluding simple febrile
             seizure).

          -  Receipt of any blood products, including immunoglobulin, within 6 months before the
             first study vaccination until the end of Stage 1.

          -  Current chronic use of systemic antibiotics.

          -  Received any investigational drugs, vaccines or devices within 28 days before
             administration of the first study vaccination and/or during study participation.

          -  Any neuroinflammatory or autoimmune condition, including but not limited to transverse
             myelitis, uveitis, optic neuritis, and multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Canberra Hospital, Paediatric Research and Clinical Trials</name>
      <address>
        <city>Canberra, Garran</city>
        <state>Australian Capital T</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maroubra Medical Centre</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's And Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute, Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna Ordinace Praktickeho Lekare Pro Deti A Dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicentrum 6 s.r.o</name>
      <address>
        <city>Praha 6 - Vokovice</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prakticky Lekar Pro Deti A Mladez</name>
      <address>
        <city>Tynec Nad Sazavou</city>
        <zip>257 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski dr n. med. Jerzy Brzostek</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Hanna Czajka</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska GRAVITA</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;NZOZ Praktyka Lekarza Rodzinnego &quot;&quot;Eskulap&quot;&quot; sp. z o.o.&quot;</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Lecznictwa Ambulatoryjnego &quot;Michalkowice&quot;Jarosz i Partnerzy Spolka Lekarska</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy Oddzial Pediatryczny</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Pediatrii i Chorob Infekcyjnych</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971035&amp;StudyName=Immunogenicity%2C%20Safety%20and%20Tolerability%20of%20Meningococcal%20B%20Vaccine%20in%20Healthy%20Toddlers.%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <results_first_submitted>February 19, 2018</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2018</results_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2 Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability Study</keyword>
  <keyword>rLP2086 Vaccine</keyword>
  <keyword>Healthy Toddlers</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Duration of Immunogenicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from greater than equal to (&gt;=) 12 months to &lt;24 months of age, received intramuscular injection of 60 microgram (µg) of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets the eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="132"/>
            <count group_id="B4" value="396"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.9" spread="4.08"/>
                    <measurement group_id="B2" value="17.4" spread="3.54"/>
                    <measurement group_id="B3" value="17.3" spread="3.58"/>
                    <measurement group_id="B4" value="17.3" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race: White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ethnicity: Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>1 month after Vaccination 3</time_frame>
        <population>All eligible participants randomized to study received,scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here,overall number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>All eligible participants randomized to study received,scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here,overall number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="91.1" lower_limit="78.8" upper_limit="97.5"/>
                    <measurement group_id="O4" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 [A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O3" value="71.1" lower_limit="55.7" upper_limit="83.6"/>
                    <measurement group_id="O4" value="72.0" lower_limit="57.5" upper_limit="83.8"/>
                    <measurement group_id="O5" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O6" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 [B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O4" value="85.1" lower_limit="71.7" upper_limit="93.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</title>
        <description>Local reactions included tenderness at injection site, swelling and redness collected by using an electronic diary (e-diary). Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>within 7 Days after Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1</title>
          <description>Local reactions included tenderness at injection site, swelling and redness collected by using an electronic diary (e-diary). Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O3" value="59.1" lower_limit="43.2" upper_limit="73.7"/>
                    <measurement group_id="O4" value="50.9" lower_limit="41.2" upper_limit="60.6"/>
                    <measurement group_id="O5" value="64.5" lower_limit="54.9" upper_limit="73.4"/>
                    <measurement group_id="O6" value="57.7" lower_limit="50.9" upper_limit="64.3"/>
                    <measurement group_id="O7" value="15.2" lower_limit="7.5" upper_limit="26.1"/>
                    <measurement group_id="O8" value="19.7" lower_limit="10.9" upper_limit="31.3"/>
                    <measurement group_id="O9" value="17.4" lower_limit="11.4" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="27.3" lower_limit="19.2" upper_limit="36.6"/>
                    <measurement group_id="O5" value="34.5" lower_limit="25.7" upper_limit="44.2"/>
                    <measurement group_id="O6" value="30.9" lower_limit="24.9" upper_limit="37.5"/>
                    <measurement group_id="O7" value="12.1" lower_limit="5.4" upper_limit="22.5"/>
                    <measurement group_id="O8" value="19.7" lower_limit="10.9" upper_limit="31.3"/>
                    <measurement group_id="O9" value="15.9" lower_limit="10.1" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O4" value="20.9" lower_limit="13.7" upper_limit="29.7"/>
                    <measurement group_id="O5" value="24.5" lower_limit="16.8" upper_limit="33.7"/>
                    <measurement group_id="O6" value="22.7" lower_limit="17.4" upper_limit="28.8"/>
                    <measurement group_id="O7" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="1.5" lower_limit="0.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="2.7" lower_limit="0.6" upper_limit="7.8"/>
                    <measurement group_id="O5" value="5.5" lower_limit="2.0" upper_limit="11.5"/>
                    <measurement group_id="O6" value="4.1" lower_limit="1.9" upper_limit="7.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="54.5" lower_limit="38.8" upper_limit="69.6"/>
                    <measurement group_id="O4" value="50.9" lower_limit="41.2" upper_limit="60.6"/>
                    <measurement group_id="O5" value="42.7" lower_limit="33.3" upper_limit="52.5"/>
                    <measurement group_id="O6" value="46.8" lower_limit="40.1" upper_limit="53.6"/>
                    <measurement group_id="O7" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O8" value="16.7" lower_limit="8.6" upper_limit="27.9"/>
                    <measurement group_id="O9" value="15.2" lower_limit="9.5" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="34.1" lower_limit="20.5" upper_limit="49.9"/>
                    <measurement group_id="O4" value="35.5" lower_limit="26.6" upper_limit="45.1"/>
                    <measurement group_id="O5" value="21.8" lower_limit="14.5" upper_limit="30.7"/>
                    <measurement group_id="O6" value="28.6" lower_limit="22.8" upper_limit="35.1"/>
                    <measurement group_id="O7" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O8" value="16.7" lower_limit="8.6" upper_limit="27.9"/>
                    <measurement group_id="O9" value="15.2" lower_limit="9.5" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O4" value="14.5" lower_limit="8.5" upper_limit="22.5"/>
                    <measurement group_id="O5" value="19.1" lower_limit="12.2" upper_limit="27.7"/>
                    <measurement group_id="O6" value="16.8" lower_limit="12.1" upper_limit="22.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.3" upper_limit="3.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="29.5" lower_limit="16.8" upper_limit="45.2"/>
                    <measurement group_id="O4" value="30.0" lower_limit="21.6" upper_limit="39.5"/>
                    <measurement group_id="O5" value="27.3" lower_limit="19.2" upper_limit="36.6"/>
                    <measurement group_id="O6" value="28.6" lower_limit="22.8" upper_limit="35.1"/>
                    <measurement group_id="O7" value="7.6" lower_limit="2.5" upper_limit="16.8"/>
                    <measurement group_id="O8" value="12.1" lower_limit="5.4" upper_limit="22.5"/>
                    <measurement group_id="O9" value="9.8" lower_limit="5.3" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O4" value="15.5" lower_limit="9.3" upper_limit="23.6"/>
                    <measurement group_id="O5" value="19.1" lower_limit="12.2" upper_limit="27.7"/>
                    <measurement group_id="O6" value="17.3" lower_limit="12.5" upper_limit="22.9"/>
                    <measurement group_id="O7" value="7.6" lower_limit="2.5" upper_limit="16.8"/>
                    <measurement group_id="O8" value="12.1" lower_limit="5.4" upper_limit="22.5"/>
                    <measurement group_id="O9" value="9.8" lower_limit="5.3" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="13.6" lower_limit="7.8" upper_limit="21.5"/>
                    <measurement group_id="O5" value="8.2" lower_limit="3.8" upper_limit="15.0"/>
                    <measurement group_id="O6" value="10.9" lower_limit="7.1" upper_limit="15.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</title>
        <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>within 7 Days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2</title>
          <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="212"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O3" value="47.7" lower_limit="32.5" upper_limit="63.3"/>
                    <measurement group_id="O4" value="45.7" lower_limit="36.0" upper_limit="55.7"/>
                    <measurement group_id="O5" value="60.7" lower_limit="50.8" upper_limit="70.0"/>
                    <measurement group_id="O6" value="53.3" lower_limit="46.3" upper_limit="60.2"/>
                    <measurement group_id="O7" value="14.3" lower_limit="6.7" upper_limit="25.4"/>
                    <measurement group_id="O8" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O9" value="14.8" lower_limit="9.2" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.7" upper_limit="41.2"/>
                    <measurement group_id="O5" value="32.7" lower_limit="24.0" upper_limit="42.5"/>
                    <measurement group_id="O6" value="32.1" lower_limit="25.8" upper_limit="38.8"/>
                    <measurement group_id="O7" value="12.7" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O8" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O9" value="14.1" lower_limit="8.6" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="12.4" lower_limit="6.8" upper_limit="20.2"/>
                    <measurement group_id="O5" value="24.3" lower_limit="16.5" upper_limit="33.5"/>
                    <measurement group_id="O6" value="18.4" lower_limit="13.4" upper_limit="24.3"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.7"/>
                    <measurement group_id="O5" value="3.7" lower_limit="1.0" upper_limit="9.3"/>
                    <measurement group_id="O6" value="2.8" lower_limit="1.0" upper_limit="6.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O2" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="40.9" lower_limit="26.3" upper_limit="56.8"/>
                    <measurement group_id="O4" value="33.3" lower_limit="24.4" upper_limit="43.2"/>
                    <measurement group_id="O5" value="38.3" lower_limit="29.1" upper_limit="48.2"/>
                    <measurement group_id="O6" value="35.8" lower_limit="29.4" upper_limit="42.7"/>
                    <measurement group_id="O7" value="6.3" lower_limit="1.8" upper_limit="15.5"/>
                    <measurement group_id="O8" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O9" value="7.8" lower_limit="3.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="34.1" lower_limit="20.5" upper_limit="49.9"/>
                    <measurement group_id="O4" value="21.9" lower_limit="14.4" upper_limit="31.0"/>
                    <measurement group_id="O5" value="23.4" lower_limit="15.7" upper_limit="32.5"/>
                    <measurement group_id="O6" value="22.6" lower_limit="17.2" upper_limit="28.9"/>
                    <measurement group_id="O7" value="6.3" lower_limit="1.8" upper_limit="15.5"/>
                    <measurement group_id="O8" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O9" value="7.8" lower_limit="3.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.4" upper_limit="18.7"/>
                    <measurement group_id="O4" value="11.4" lower_limit="6.0" upper_limit="19.1"/>
                    <measurement group_id="O5" value="15.0" lower_limit="8.8" upper_limit="23.1"/>
                    <measurement group_id="O6" value="13.2" lower_limit="9.0" upper_limit="18.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="22.7" lower_limit="11.5" upper_limit="37.8"/>
                    <measurement group_id="O4" value="21.0" lower_limit="13.6" upper_limit="30.0"/>
                    <measurement group_id="O5" value="19.6" lower_limit="12.6" upper_limit="28.4"/>
                    <measurement group_id="O6" value="20.3" lower_limit="15.1" upper_limit="26.3"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O9" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O4" value="14.3" lower_limit="8.2" upper_limit="22.5"/>
                    <measurement group_id="O5" value="13.1" lower_limit="7.3" upper_limit="21.0"/>
                    <measurement group_id="O6" value="13.7" lower_limit="9.4" upper_limit="19.1"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O9" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.4" upper_limit="18.7"/>
                    <measurement group_id="O4" value="6.7" lower_limit="2.7" upper_limit="13.3"/>
                    <measurement group_id="O5" value="5.6" lower_limit="2.1" upper_limit="11.8"/>
                    <measurement group_id="O6" value="6.1" lower_limit="3.3" upper_limit="10.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</title>
        <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
        <time_frame>within 7 Days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3</title>
          <description>Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (&gt;7.0 cm).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="108"/>
                <count group_id="O6" value="212"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="32.2" upper_limit="75.6"/>
                    <measurement group_id="O2" value="59.1" lower_limit="36.4" upper_limit="79.3"/>
                    <measurement group_id="O3" value="56.8" lower_limit="41.0" upper_limit="71.7"/>
                    <measurement group_id="O4" value="51.9" lower_limit="41.9" upper_limit="61.8"/>
                    <measurement group_id="O5" value="62.0" lower_limit="52.2" upper_limit="71.2"/>
                    <measurement group_id="O6" value="57.1" lower_limit="50.1" upper_limit="63.8"/>
                    <measurement group_id="O7" value="16.9" lower_limit="8.8" upper_limit="28.3"/>
                    <measurement group_id="O8" value="14.3" lower_limit="6.7" upper_limit="25.4"/>
                    <measurement group_id="O9" value="15.6" lower_limit="9.8" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O4" value="29.8" lower_limit="21.2" upper_limit="39.6"/>
                    <measurement group_id="O5" value="34.3" lower_limit="25.4" upper_limit="44.0"/>
                    <measurement group_id="O6" value="32.1" lower_limit="25.8" upper_limit="38.8"/>
                    <measurement group_id="O7" value="12.3" lower_limit="5.5" upper_limit="22.8"/>
                    <measurement group_id="O8" value="12.7" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O9" value="12.5" lower_limit="7.3" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="25.0" lower_limit="13.2" upper_limit="40.3"/>
                    <measurement group_id="O4" value="17.3" lower_limit="10.6" upper_limit="26.0"/>
                    <measurement group_id="O5" value="22.2" lower_limit="14.8" upper_limit="31.2"/>
                    <measurement group_id="O6" value="19.8" lower_limit="14.7" upper_limit="25.8"/>
                    <measurement group_id="O7" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="3.1" lower_limit="0.9" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.9"/>
                    <measurement group_id="O5" value="5.6" lower_limit="2.1" upper_limit="11.7"/>
                    <measurement group_id="O6" value="5.2" lower_limit="2.6" upper_limit="9.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O3" value="38.6" lower_limit="24.4" upper_limit="54.5"/>
                    <measurement group_id="O4" value="32.7" lower_limit="23.8" upper_limit="42.6"/>
                    <measurement group_id="O5" value="33.3" lower_limit="24.6" upper_limit="43.1"/>
                    <measurement group_id="O6" value="33.0" lower_limit="26.7" upper_limit="39.8"/>
                    <measurement group_id="O7" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O8" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O9" value="7.8" lower_limit="3.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="29.5" lower_limit="16.8" upper_limit="45.2"/>
                    <measurement group_id="O4" value="23.1" lower_limit="15.4" upper_limit="32.4"/>
                    <measurement group_id="O5" value="18.5" lower_limit="11.7" upper_limit="27.1"/>
                    <measurement group_id="O6" value="20.8" lower_limit="15.5" upper_limit="26.8"/>
                    <measurement group_id="O7" value="6.2" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O8" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O9" value="7.0" lower_limit="3.3" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="9.1" lower_limit="2.5" upper_limit="21.7"/>
                    <measurement group_id="O4" value="8.7" lower_limit="4.0" upper_limit="15.8"/>
                    <measurement group_id="O5" value="14.8" lower_limit="8.7" upper_limit="22.9"/>
                    <measurement group_id="O6" value="11.8" lower_limit="7.8" upper_limit="16.9"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="22.7" lower_limit="11.5" upper_limit="37.8"/>
                    <measurement group_id="O4" value="23.1" lower_limit="15.4" upper_limit="32.4"/>
                    <measurement group_id="O5" value="22.2" lower_limit="14.8" upper_limit="31.2"/>
                    <measurement group_id="O6" value="22.6" lower_limit="17.2" upper_limit="28.9"/>
                    <measurement group_id="O7" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O8" value="6.3" lower_limit="1.8" upper_limit="15.5"/>
                    <measurement group_id="O9" value="5.5" lower_limit="2.2" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="16.3" lower_limit="9.8" upper_limit="24.9"/>
                    <measurement group_id="O5" value="11.1" lower_limit="5.9" upper_limit="18.6"/>
                    <measurement group_id="O6" value="13.7" lower_limit="9.4" upper_limit="19.1"/>
                    <measurement group_id="O7" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O8" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O9" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="5.8" lower_limit="2.1" upper_limit="12.1"/>
                    <measurement group_id="O5" value="11.1" lower_limit="5.9" upper_limit="18.6"/>
                    <measurement group_id="O6" value="8.5" lower_limit="5.1" upper_limit="13.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</title>
        <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
        <time_frame>within 7 Days after Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1</title>
          <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="28.2" lower_limit="20.0" upper_limit="37.6"/>
                    <measurement group_id="O5" value="27.3" lower_limit="19.2" upper_limit="36.6"/>
                    <measurement group_id="O6" value="27.7" lower_limit="21.9" upper_limit="34.1"/>
                    <measurement group_id="O7" value="10.6" lower_limit="4.4" upper_limit="20.6"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="6.1" lower_limit="2.7" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O4" value="7.3" lower_limit="3.2" upper_limit="13.8"/>
                    <measurement group_id="O5" value="7.3" lower_limit="3.2" upper_limit="13.8"/>
                    <measurement group_id="O6" value="7.3" lower_limit="4.2" upper_limit="11.5"/>
                    <measurement group_id="O7" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="3.8" lower_limit="1.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="14.5" lower_limit="8.5" upper_limit="22.5"/>
                    <measurement group_id="O5" value="13.6" lower_limit="7.8" upper_limit="21.5"/>
                    <measurement group_id="O6" value="14.1" lower_limit="9.8" upper_limit="19.4"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="4.5" lower_limit="1.5" upper_limit="10.3"/>
                    <measurement group_id="O5" value="3.6" lower_limit="1.0" upper_limit="9.0"/>
                    <measurement group_id="O6" value="4.1" lower_limit="1.9" upper_limit="7.6"/>
                    <measurement group_id="O7" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="1.5" lower_limit="0.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to &lt;=40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="1.8" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O6" value="1.8" lower_limit="0.5" upper_limit="4.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="40.7" upper_limit="82.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O3" value="56.8" lower_limit="41.0" upper_limit="71.7"/>
                    <measurement group_id="O4" value="71.8" lower_limit="62.4" upper_limit="80.0"/>
                    <measurement group_id="O5" value="60.9" lower_limit="51.1" upper_limit="70.1"/>
                    <measurement group_id="O6" value="66.4" lower_limit="59.7" upper_limit="72.6"/>
                    <measurement group_id="O7" value="40.9" lower_limit="29.0" upper_limit="53.7"/>
                    <measurement group_id="O8" value="33.3" lower_limit="22.2" upper_limit="46.0"/>
                    <measurement group_id="O9" value="37.1" lower_limit="28.9" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O4" value="19.1" lower_limit="12.2" upper_limit="27.7"/>
                    <measurement group_id="O5" value="16.4" lower_limit="10.0" upper_limit="24.6"/>
                    <measurement group_id="O6" value="17.7" lower_limit="12.9" upper_limit="23.4"/>
                    <measurement group_id="O7" value="10.6" lower_limit="4.4" upper_limit="20.6"/>
                    <measurement group_id="O8" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O9" value="12.1" lower_limit="7.1" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="46.4" lower_limit="36.8" upper_limit="56.1"/>
                    <measurement group_id="O5" value="39.1" lower_limit="29.9" upper_limit="48.9"/>
                    <measurement group_id="O6" value="42.7" lower_limit="36.1" upper_limit="49.6"/>
                    <measurement group_id="O7" value="30.3" lower_limit="19.6" upper_limit="42.9"/>
                    <measurement group_id="O8" value="16.7" lower_limit="8.6" upper_limit="27.9"/>
                    <measurement group_id="O9" value="23.5" lower_limit="16.5" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="6.4" lower_limit="2.6" upper_limit="12.7"/>
                    <measurement group_id="O5" value="5.5" lower_limit="2.0" upper_limit="11.5"/>
                    <measurement group_id="O6" value="5.9" lower_limit="3.2" upper_limit="9.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O9" value="1.5" lower_limit="0.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                    <measurement group_id="O4" value="45.5" lower_limit="35.9" upper_limit="55.2"/>
                    <measurement group_id="O5" value="42.7" lower_limit="33.3" upper_limit="52.5"/>
                    <measurement group_id="O6" value="44.1" lower_limit="37.4" upper_limit="50.9"/>
                    <measurement group_id="O7" value="25.8" lower_limit="15.8" upper_limit="38.0"/>
                    <measurement group_id="O8" value="10.6" lower_limit="4.4" upper_limit="20.6"/>
                    <measurement group_id="O9" value="18.2" lower_limit="12.0" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O3" value="34.1" lower_limit="20.5" upper_limit="49.9"/>
                    <measurement group_id="O4" value="28.2" lower_limit="20.0" upper_limit="37.6"/>
                    <measurement group_id="O5" value="24.5" lower_limit="16.8" upper_limit="33.7"/>
                    <measurement group_id="O6" value="26.4" lower_limit="20.7" upper_limit="32.7"/>
                    <measurement group_id="O7" value="16.7" lower_limit="8.6" upper_limit="27.9"/>
                    <measurement group_id="O8" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O9" value="11.4" lower_limit="6.5" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="9.1" lower_limit="2.5" upper_limit="21.7"/>
                    <measurement group_id="O4" value="11.8" lower_limit="6.4" upper_limit="19.4"/>
                    <measurement group_id="O5" value="15.5" lower_limit="9.3" upper_limit="23.6"/>
                    <measurement group_id="O6" value="13.6" lower_limit="9.4" upper_limit="18.9"/>
                    <measurement group_id="O7" value="7.6" lower_limit="2.5" upper_limit="16.8"/>
                    <measurement group_id="O8" value="4.5" lower_limit="0.9" upper_limit="12.7"/>
                    <measurement group_id="O9" value="6.1" lower_limit="2.7" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="5.5" lower_limit="2.0" upper_limit="11.5"/>
                    <measurement group_id="O5" value="2.7" lower_limit="0.6" upper_limit="7.8"/>
                    <measurement group_id="O6" value="4.1" lower_limit="1.9" upper_limit="7.6"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decrease appetite: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="44.5" lower_limit="35.1" upper_limit="54.3"/>
                    <measurement group_id="O5" value="46.4" lower_limit="36.8" upper_limit="56.1"/>
                    <measurement group_id="O6" value="45.5" lower_limit="38.7" upper_limit="52.3"/>
                    <measurement group_id="O7" value="34.8" lower_limit="23.5" upper_limit="47.6"/>
                    <measurement group_id="O8" value="10.6" lower_limit="4.4" upper_limit="20.6"/>
                    <measurement group_id="O9" value="22.7" lower_limit="15.9" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decrease appetite: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O4" value="16.4" lower_limit="10.0" upper_limit="24.6"/>
                    <measurement group_id="O5" value="24.5" lower_limit="16.8" upper_limit="33.7"/>
                    <measurement group_id="O6" value="20.5" lower_limit="15.3" upper_limit="26.4"/>
                    <measurement group_id="O7" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O8" value="7.6" lower_limit="2.5" upper_limit="16.8"/>
                    <measurement group_id="O9" value="10.6" lower_limit="5.9" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decrease appetite: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="25.5" lower_limit="17.6" upper_limit="34.6"/>
                    <measurement group_id="O5" value="14.5" lower_limit="8.5" upper_limit="22.5"/>
                    <measurement group_id="O6" value="20.0" lower_limit="14.9" upper_limit="25.9"/>
                    <measurement group_id="O7" value="18.2" lower_limit="9.8" upper_limit="29.6"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="9.8" lower_limit="5.3" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decrease appetite: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="2.7" lower_limit="0.6" upper_limit="7.8"/>
                    <measurement group_id="O5" value="7.3" lower_limit="3.2" upper_limit="13.8"/>
                    <measurement group_id="O6" value="5.0" lower_limit="2.5" upper_limit="8.8"/>
                    <measurement group_id="O7" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="2.3" lower_limit="0.5" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="59.1" lower_limit="36.4" upper_limit="79.3"/>
                    <measurement group_id="O3" value="52.3" lower_limit="36.7" upper_limit="67.5"/>
                    <measurement group_id="O4" value="52.7" lower_limit="43.0" upper_limit="62.3"/>
                    <measurement group_id="O5" value="40.9" lower_limit="31.6" upper_limit="50.7"/>
                    <measurement group_id="O6" value="46.8" lower_limit="40.1" upper_limit="53.6"/>
                    <measurement group_id="O7" value="24.2" lower_limit="14.5" upper_limit="36.4"/>
                    <measurement group_id="O8" value="15.2" lower_limit="7.5" upper_limit="26.1"/>
                    <measurement group_id="O9" value="19.7" lower_limit="13.3" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</title>
        <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
        <time_frame>within 7 Days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2</title>
          <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="212"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="14.3" lower_limit="8.2" upper_limit="22.5"/>
                    <measurement group_id="O5" value="14.0" lower_limit="8.1" upper_limit="22.1"/>
                    <measurement group_id="O6" value="14.2" lower_limit="9.8" upper_limit="19.6"/>
                    <measurement group_id="O7" value="6.3" lower_limit="1.8" upper_limit="15.5"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O9" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.4" upper_limit="18.7"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.8"/>
                    <measurement group_id="O5" value="8.4" lower_limit="3.9" upper_limit="15.4"/>
                    <measurement group_id="O6" value="6.6" lower_limit="3.7" upper_limit="10.8"/>
                    <measurement group_id="O7" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O9" value="3.9" lower_limit="1.3" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="6.7" lower_limit="2.7" upper_limit="13.3"/>
                    <measurement group_id="O5" value="2.8" lower_limit="0.6" upper_limit="8.0"/>
                    <measurement group_id="O6" value="4.7" lower_limit="2.3" upper_limit="8.5"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.7"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="4.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to &lt;=40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="0.9" lower_limit="0.1" upper_limit="3.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="45.5" lower_limit="30.4" upper_limit="61.2"/>
                    <measurement group_id="O4" value="54.3" lower_limit="44.3" upper_limit="64.0"/>
                    <measurement group_id="O5" value="55.1" lower_limit="45.2" upper_limit="64.8"/>
                    <measurement group_id="O6" value="54.7" lower_limit="47.8" upper_limit="61.5"/>
                    <measurement group_id="O7" value="31.7" lower_limit="20.6" upper_limit="44.7"/>
                    <measurement group_id="O8" value="18.5" lower_limit="9.9" upper_limit="30.0"/>
                    <measurement group_id="O9" value="25.0" lower_limit="17.8" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="29.5" lower_limit="16.8" upper_limit="45.2"/>
                    <measurement group_id="O4" value="19.0" lower_limit="12.0" upper_limit="27.9"/>
                    <measurement group_id="O5" value="18.7" lower_limit="11.8" upper_limit="27.4"/>
                    <measurement group_id="O6" value="18.9" lower_limit="13.8" upper_limit="24.8"/>
                    <measurement group_id="O7" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O8" value="6.2" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O9" value="7.0" lower_limit="3.3" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="5.2" upper_limit="27.4"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.7" upper_limit="41.2"/>
                    <measurement group_id="O5" value="34.6" lower_limit="25.6" upper_limit="44.4"/>
                    <measurement group_id="O6" value="33.0" lower_limit="26.7" upper_limit="39.8"/>
                    <measurement group_id="O7" value="22.2" lower_limit="12.7" upper_limit="34.5"/>
                    <measurement group_id="O8" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O9" value="15.6" lower_limit="9.8" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.5"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O6" value="2.8" lower_limit="1.0" upper_limit="6.1"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O9" value="2.3" lower_limit="0.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O4" value="37.1" lower_limit="27.9" upper_limit="47.1"/>
                    <measurement group_id="O5" value="24.3" lower_limit="16.5" upper_limit="33.5"/>
                    <measurement group_id="O6" value="30.7" lower_limit="24.5" upper_limit="37.3"/>
                    <measurement group_id="O7" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                    <measurement group_id="O8" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O9" value="11.7" lower_limit="6.7" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="13.6" lower_limit="5.2" upper_limit="27.4"/>
                    <measurement group_id="O4" value="22.9" lower_limit="15.2" upper_limit="32.1"/>
                    <measurement group_id="O5" value="14.0" lower_limit="8.1" upper_limit="22.1"/>
                    <measurement group_id="O6" value="18.4" lower_limit="13.4" upper_limit="24.3"/>
                    <measurement group_id="O7" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O8" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O9" value="7.0" lower_limit="3.3" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="13.3" lower_limit="7.5" upper_limit="21.4"/>
                    <measurement group_id="O5" value="8.4" lower_limit="3.9" upper_limit="15.4"/>
                    <measurement group_id="O6" value="10.8" lower_limit="7.0" upper_limit="15.8"/>
                    <measurement group_id="O7" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="3.9" lower_limit="1.3" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.3" upper_limit="4.1"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="13.9" upper_limit="54.9"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="25.0" lower_limit="13.2" upper_limit="40.3"/>
                    <measurement group_id="O4" value="41.0" lower_limit="31.5" upper_limit="51.0"/>
                    <measurement group_id="O5" value="31.8" lower_limit="23.1" upper_limit="41.5"/>
                    <measurement group_id="O6" value="36.3" lower_limit="29.8" upper_limit="43.2"/>
                    <measurement group_id="O7" value="22.2" lower_limit="12.7" upper_limit="34.5"/>
                    <measurement group_id="O8" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O9" value="18.0" lower_limit="11.7" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="22.7" lower_limit="11.5" upper_limit="37.8"/>
                    <measurement group_id="O4" value="19.0" lower_limit="12.0" upper_limit="27.9"/>
                    <measurement group_id="O5" value="19.6" lower_limit="12.6" upper_limit="28.4"/>
                    <measurement group_id="O6" value="19.3" lower_limit="14.3" upper_limit="25.3"/>
                    <measurement group_id="O7" value="11.1" lower_limit="4.6" upper_limit="21.6"/>
                    <measurement group_id="O8" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O9" value="9.4" lower_limit="4.9" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="17.1" lower_limit="10.5" upper_limit="25.7"/>
                    <measurement group_id="O5" value="7.5" lower_limit="3.3" upper_limit="14.2"/>
                    <measurement group_id="O6" value="12.3" lower_limit="8.2" upper_limit="17.5"/>
                    <measurement group_id="O7" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O8" value="6.2" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O9" value="7.8" lower_limit="3.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="4.8" lower_limit="1.6" upper_limit="10.8"/>
                    <measurement group_id="O5" value="4.7" lower_limit="1.5" upper_limit="10.6"/>
                    <measurement group_id="O6" value="4.7" lower_limit="2.3" upper_limit="8.5"/>
                    <measurement group_id="O7" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="35.2" lower_limit="26.2" upper_limit="45.2"/>
                    <measurement group_id="O5" value="31.8" lower_limit="23.1" upper_limit="41.5"/>
                    <measurement group_id="O6" value="33.5" lower_limit="27.2" upper_limit="40.3"/>
                    <measurement group_id="O7" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                    <measurement group_id="O8" value="10.8" lower_limit="4.4" upper_limit="20.9"/>
                    <measurement group_id="O9" value="14.8" lower_limit="9.2" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</title>
        <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
        <time_frame>within 7 Days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3</title>
          <description>Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, &gt;39.5 to 40.0 degree C and &gt;40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="108"/>
                <count group_id="O6" value="212"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="10.6" lower_limit="5.4" upper_limit="18.1"/>
                    <measurement group_id="O5" value="14.8" lower_limit="8.7" upper_limit="22.9"/>
                    <measurement group_id="O6" value="12.7" lower_limit="8.6" upper_limit="18.0"/>
                    <measurement group_id="O7" value="4.6" lower_limit="1.0" upper_limit="12.9"/>
                    <measurement group_id="O8" value="7.9" lower_limit="2.6" upper_limit="17.6"/>
                    <measurement group_id="O9" value="6.3" lower_limit="2.7" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="6.7" lower_limit="2.7" upper_limit="13.4"/>
                    <measurement group_id="O5" value="6.5" lower_limit="2.6" upper_limit="12.9"/>
                    <measurement group_id="O6" value="6.6" lower_limit="3.7" upper_limit="10.8"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O8" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O9" value="3.9" lower_limit="1.3" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.2" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.4" lower_limit="0.8" upper_limit="5.4"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39 to &lt;39.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="1.0" upper_limit="9.2"/>
                    <measurement group_id="O6" value="2.4" lower_limit="0.8" upper_limit="5.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.5 to &lt;=40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="2.8" lower_limit="0.6" upper_limit="7.9"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.3" upper_limit="4.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O3" value="36.4" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="56.7" lower_limit="46.7" upper_limit="66.4"/>
                    <measurement group_id="O5" value="44.4" lower_limit="34.9" upper_limit="54.3"/>
                    <measurement group_id="O6" value="50.5" lower_limit="43.5" upper_limit="57.4"/>
                    <measurement group_id="O7" value="24.6" lower_limit="14.8" upper_limit="36.9"/>
                    <measurement group_id="O8" value="30.2" lower_limit="19.2" upper_limit="43.0"/>
                    <measurement group_id="O9" value="27.3" lower_limit="19.8" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O4" value="27.9" lower_limit="19.5" upper_limit="37.5"/>
                    <measurement group_id="O5" value="19.4" lower_limit="12.5" upper_limit="28.2"/>
                    <measurement group_id="O6" value="23.6" lower_limit="18.0" upper_limit="29.9"/>
                    <measurement group_id="O7" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O8" value="15.9" lower_limit="7.9" upper_limit="27.3"/>
                    <measurement group_id="O9" value="12.5" lower_limit="7.3" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O4" value="26.0" lower_limit="17.9" upper_limit="35.5"/>
                    <measurement group_id="O5" value="24.1" lower_limit="16.4" upper_limit="33.3"/>
                    <measurement group_id="O6" value="25.0" lower_limit="19.3" upper_limit="31.4"/>
                    <measurement group_id="O7" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O8" value="12.7" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O9" value="13.3" lower_limit="7.9" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="4.8"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="5.2" upper_limit="27.4"/>
                    <measurement group_id="O4" value="37.5" lower_limit="28.2" upper_limit="47.5"/>
                    <measurement group_id="O5" value="30.6" lower_limit="22.1" upper_limit="40.2"/>
                    <measurement group_id="O6" value="34.0" lower_limit="27.6" upper_limit="40.8"/>
                    <measurement group_id="O7" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O8" value="12.7" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O9" value="13.3" lower_limit="7.9" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="5.2" upper_limit="27.4"/>
                    <measurement group_id="O4" value="24.0" lower_limit="16.2" upper_limit="33.4"/>
                    <measurement group_id="O5" value="23.1" lower_limit="15.6" upper_limit="32.2"/>
                    <measurement group_id="O6" value="23.6" lower_limit="18.0" upper_limit="29.9"/>
                    <measurement group_id="O7" value="10.8" lower_limit="4.4" upper_limit="20.9"/>
                    <measurement group_id="O8" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O9" value="10.2" lower_limit="5.5" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="10.6" lower_limit="5.4" upper_limit="18.1"/>
                    <measurement group_id="O5" value="6.5" lower_limit="2.6" upper_limit="12.9"/>
                    <measurement group_id="O6" value="8.5" lower_limit="5.1" upper_limit="13.1"/>
                    <measurement group_id="O7" value="3.1" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="2.3" lower_limit="0.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="4.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O4" value="33.7" lower_limit="24.7" upper_limit="43.6"/>
                    <measurement group_id="O5" value="35.2" lower_limit="26.2" upper_limit="45.0"/>
                    <measurement group_id="O6" value="34.4" lower_limit="28.1" upper_limit="41.2"/>
                    <measurement group_id="O7" value="16.9" lower_limit="8.8" upper_limit="28.3"/>
                    <measurement group_id="O8" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                    <measurement group_id="O9" value="18.0" lower_limit="11.7" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O3" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O4" value="15.4" lower_limit="9.1" upper_limit="23.8"/>
                    <measurement group_id="O5" value="18.5" lower_limit="11.7" upper_limit="27.1"/>
                    <measurement group_id="O6" value="17.0" lower_limit="12.2" upper_limit="22.7"/>
                    <measurement group_id="O7" value="9.2" lower_limit="3.5" upper_limit="19.0"/>
                    <measurement group_id="O8" value="15.9" lower_limit="7.9" upper_limit="27.3"/>
                    <measurement group_id="O9" value="12.5" lower_limit="7.3" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="14.4" lower_limit="8.3" upper_limit="22.7"/>
                    <measurement group_id="O5" value="14.8" lower_limit="8.7" upper_limit="22.9"/>
                    <measurement group_id="O6" value="14.6" lower_limit="10.2" upper_limit="20.1"/>
                    <measurement group_id="O7" value="7.7" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="4.7" lower_limit="1.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of or decreased appetite: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.1" upper_limit="9.6"/>
                    <measurement group_id="O5" value="1.9" lower_limit="0.2" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.8" lower_limit="1.0" upper_limit="6.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic medication use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O4" value="34.6" lower_limit="25.6" upper_limit="44.6"/>
                    <measurement group_id="O5" value="33.3" lower_limit="24.6" upper_limit="43.1"/>
                    <measurement group_id="O6" value="34.0" lower_limit="27.6" upper_limit="40.8"/>
                    <measurement group_id="O7" value="13.8" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O8" value="15.9" lower_limit="7.9" upper_limit="27.3"/>
                    <measurement group_id="O9" value="14.8" lower_limit="9.2" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 1</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>within 30 Days after Vaccination 1</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 1</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O3" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O4" value="38.2" lower_limit="29.1" upper_limit="47.9"/>
                    <measurement group_id="O5" value="41.8" lower_limit="32.5" upper_limit="51.6"/>
                    <measurement group_id="O6" value="40.0" lower_limit="33.5" upper_limit="46.8"/>
                    <measurement group_id="O7" value="33.3" lower_limit="22.2" upper_limit="46.0"/>
                    <measurement group_id="O8" value="27.3" lower_limit="17.0" upper_limit="39.6"/>
                    <measurement group_id="O9" value="30.3" lower_limit="22.6" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.3" upper_limit="3.9"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="1.5" lower_limit="0.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="18.2" lower_limit="11.5" upper_limit="26.7"/>
                    <measurement group_id="O5" value="19.1" lower_limit="12.2" upper_limit="27.7"/>
                    <measurement group_id="O6" value="18.6" lower_limit="13.7" upper_limit="24.4"/>
                    <measurement group_id="O7" value="18.2" lower_limit="9.8" upper_limit="29.6"/>
                    <measurement group_id="O8" value="16.7" lower_limit="8.6" upper_limit="27.9"/>
                    <measurement group_id="O9" value="17.4" lower_limit="11.4" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>within 30 Days after Vaccination 2</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="108"/>
                <count group_id="O6" value="213"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="22.7" lower_limit="11.5" upper_limit="37.8"/>
                    <measurement group_id="O4" value="34.3" lower_limit="25.3" upper_limit="44.2"/>
                    <measurement group_id="O5" value="34.3" lower_limit="25.4" upper_limit="44.0"/>
                    <measurement group_id="O6" value="34.3" lower_limit="27.9" upper_limit="41.1"/>
                    <measurement group_id="O7" value="24.2" lower_limit="14.5" upper_limit="36.4"/>
                    <measurement group_id="O8" value="32.3" lower_limit="21.2" upper_limit="45.1"/>
                    <measurement group_id="O9" value="28.2" lower_limit="20.7" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.0" upper_limit="9.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0.5" upper_limit="4.7"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="11.4" lower_limit="3.8" upper_limit="24.6"/>
                    <measurement group_id="O4" value="16.2" lower_limit="9.7" upper_limit="24.7"/>
                    <measurement group_id="O5" value="18.5" lower_limit="11.7" upper_limit="27.1"/>
                    <measurement group_id="O6" value="17.4" lower_limit="12.5" upper_limit="23.1"/>
                    <measurement group_id="O7" value="13.6" lower_limit="6.4" upper_limit="24.3"/>
                    <measurement group_id="O8" value="23.1" lower_limit="13.5" upper_limit="35.2"/>
                    <measurement group_id="O9" value="18.3" lower_limit="12.1" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 3</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
        <time_frame>within 30 Days after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 3</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.</description>
          <population>Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="108"/>
                <count group_id="O6" value="212"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="64"/>
                <count group_id="O9" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5.2" upper_limit="40.3"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="29.5" lower_limit="16.8" upper_limit="45.2"/>
                    <measurement group_id="O4" value="25.0" lower_limit="17.0" upper_limit="34.4"/>
                    <measurement group_id="O5" value="30.6" lower_limit="22.1" upper_limit="40.2"/>
                    <measurement group_id="O6" value="27.8" lower_limit="21.9" upper_limit="34.4"/>
                    <measurement group_id="O7" value="24.6" lower_limit="14.8" upper_limit="36.9"/>
                    <measurement group_id="O8" value="28.1" lower_limit="17.6" upper_limit="40.8"/>
                    <measurement group_id="O9" value="26.4" lower_limit="19.0" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O9" value="0.8" lower_limit="0.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O4" value="13.5" lower_limit="7.6" upper_limit="21.6"/>
                    <measurement group_id="O5" value="16.7" lower_limit="10.2" upper_limit="25.1"/>
                    <measurement group_id="O6" value="15.1" lower_limit="10.6" upper_limit="20.6"/>
                    <measurement group_id="O7" value="12.3" lower_limit="5.5" upper_limit="22.8"/>
                    <measurement group_id="O8" value="20.3" lower_limit="11.3" upper_limit="32.2"/>
                    <measurement group_id="O9" value="16.3" lower_limit="10.4" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>within 30 Days after any Vaccination</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="63.6" lower_limit="40.7" upper_limit="82.8"/>
                    <measurement group_id="O3" value="50.0" lower_limit="34.6" upper_limit="65.4"/>
                    <measurement group_id="O4" value="54.5" lower_limit="44.8" upper_limit="64.1"/>
                    <measurement group_id="O5" value="61.8" lower_limit="52.1" upper_limit="70.9"/>
                    <measurement group_id="O6" value="58.2" lower_limit="51.4" upper_limit="64.8"/>
                    <measurement group_id="O7" value="53.0" lower_limit="40.3" upper_limit="65.4"/>
                    <measurement group_id="O8" value="54.5" lower_limit="41.8" upper_limit="66.9"/>
                    <measurement group_id="O9" value="53.8" lower_limit="44.9" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="5.5" lower_limit="2.0" upper_limit="11.5"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O6" value="3.6" lower_limit="1.6" upper_limit="7.0"/>
                    <measurement group_id="O7" value="4.5" lower_limit="0.9" upper_limit="12.7"/>
                    <measurement group_id="O8" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O9" value="3.0" lower_limit="0.8" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O4" value="32.7" lower_limit="24.1" upper_limit="42.3"/>
                    <measurement group_id="O5" value="40.0" lower_limit="30.8" upper_limit="49.8"/>
                    <measurement group_id="O6" value="36.4" lower_limit="30.0" upper_limit="43.1"/>
                    <measurement group_id="O7" value="31.8" lower_limit="20.9" upper_limit="44.4"/>
                    <measurement group_id="O8" value="39.4" lower_limit="27.6" upper_limit="52.2"/>
                    <measurement group_id="O9" value="35.6" lower_limit="27.5" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From the Vaccination 1 up to 1 month after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="32.2" upper_limit="75.6"/>
                    <measurement group_id="O2" value="77.3" lower_limit="54.6" upper_limit="92.2"/>
                    <measurement group_id="O3" value="65.9" lower_limit="50.1" upper_limit="79.5"/>
                    <measurement group_id="O4" value="68.2" lower_limit="58.6" upper_limit="76.7"/>
                    <measurement group_id="O5" value="71.8" lower_limit="62.4" upper_limit="80.0"/>
                    <measurement group_id="O6" value="70.0" lower_limit="63.5" upper_limit="76.0"/>
                    <measurement group_id="O7" value="65.2" lower_limit="52.4" upper_limit="76.5"/>
                    <measurement group_id="O8" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O9" value="64.4" lower_limit="55.6" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O4" value="10.9" lower_limit="5.8" upper_limit="18.3"/>
                    <measurement group_id="O5" value="3.6" lower_limit="1.0" upper_limit="9.0"/>
                    <measurement group_id="O6" value="7.3" lower_limit="4.2" upper_limit="11.5"/>
                    <measurement group_id="O7" value="4.5" lower_limit="0.9" upper_limit="12.7"/>
                    <measurement group_id="O8" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O9" value="5.3" lower_limit="2.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="17.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="45.5" lower_limit="24.4" upper_limit="67.8"/>
                    <measurement group_id="O3" value="40.9" lower_limit="26.3" upper_limit="56.8"/>
                    <measurement group_id="O4" value="47.3" lower_limit="37.7" upper_limit="57.0"/>
                    <measurement group_id="O5" value="54.5" lower_limit="44.8" upper_limit="64.1"/>
                    <measurement group_id="O6" value="50.9" lower_limit="44.1" upper_limit="57.7"/>
                    <measurement group_id="O7" value="42.4" lower_limit="30.3" upper_limit="55.2"/>
                    <measurement group_id="O8" value="43.9" lower_limit="31.7" upper_limit="56.7"/>
                    <measurement group_id="O9" value="43.2" lower_limit="34.6" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Follow up Phase</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From 1 month after Vaccination 3 up to 6 months after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Follow up Phase</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="215"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="63"/>
                <count group_id="O9" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.4" upper_limit="18.7"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O5" value="3.7" lower_limit="1.0" upper_limit="9.3"/>
                    <measurement group_id="O6" value="2.3" lower_limit="0.8" upper_limit="5.3"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O4" value="29.6" lower_limit="21.2" upper_limit="39.2"/>
                    <measurement group_id="O5" value="32.7" lower_limit="24.0" upper_limit="42.5"/>
                    <measurement group_id="O6" value="31.2" lower_limit="25.0" upper_limit="37.8"/>
                    <measurement group_id="O7" value="30.8" lower_limit="19.9" upper_limit="43.4"/>
                    <measurement group_id="O8" value="28.6" lower_limit="17.9" upper_limit="41.3"/>
                    <measurement group_id="O9" value="29.7" lower_limit="21.9" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC)Throughout the Study</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
        <time_frame>From Vaccination 1 up to 6 months after Vaccination 3</time_frame>
        <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC)Throughout the Study</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.</description>
          <population>Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="220"/>
                <count group_id="O7" value="66"/>
                <count group_id="O8" value="66"/>
                <count group_id="O9" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="9.1" lower_limit="2.5" upper_limit="21.7"/>
                    <measurement group_id="O4" value="10.9" lower_limit="5.8" upper_limit="18.3"/>
                    <measurement group_id="O5" value="6.4" lower_limit="2.6" upper_limit="12.7"/>
                    <measurement group_id="O6" value="8.6" lower_limit="5.3" upper_limit="13.2"/>
                    <measurement group_id="O7" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O8" value="6.1" lower_limit="1.7" upper_limit="14.8"/>
                    <measurement group_id="O9" value="6.1" lower_limit="2.7" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="32.2" upper_limit="75.6"/>
                    <measurement group_id="O2" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O3" value="61.4" lower_limit="45.5" upper_limit="75.6"/>
                    <measurement group_id="O4" value="54.5" lower_limit="44.8" upper_limit="64.1"/>
                    <measurement group_id="O5" value="62.7" lower_limit="53.0" upper_limit="71.8"/>
                    <measurement group_id="O6" value="58.6" lower_limit="51.8" upper_limit="65.2"/>
                    <measurement group_id="O7" value="59.1" lower_limit="46.3" upper_limit="71.0"/>
                    <measurement group_id="O8" value="53.0" lower_limit="40.3" upper_limit="65.4"/>
                    <measurement group_id="O9" value="56.1" lower_limit="42.7" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.0" upper_limit="2.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titer Between 12 Months to Less Than (&lt;) 24 Months &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
        <time_frame>1 Month After Vaccination 3</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titer Between 12 Months to Less Than (&lt;) 24 Months &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O2" value="89.6" lower_limit="81.7" upper_limit="94.9"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O2" value="71.6" lower_limit="61.4" upper_limit="80.4"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O2" value="86.2" lower_limit="77.5" upper_limit="92.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
        <time_frame>1 month (Mon) after Vaccination (Vac) 2</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With hSBA Titer &gt;= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).</description>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here &quot;N&quot; signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Mon after Vac2: PMB80[A22]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                    <measurement group_id="O3" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O4" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O5" value="84.0" lower_limit="70.9" upper_limit="92.8"/>
                    <measurement group_id="O6" value="74.7" lower_limit="64.8" upper_limit="83.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1Mon after Vac2:PMB2001[A56]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1Mon after Vac2:PMB2948[B24]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O2" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O3" value="57.9" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O4" value="23.8" lower_limit="12.1" upper_limit="39.5"/>
                    <measurement group_id="O5" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                    <measurement group_id="O6" value="33.7" lower_limit="23.9" upper_limit="44.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1Mon after Vac2:PMB2707[B44]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="72.3" lower_limit="57.4" upper_limit="84.4"/>
                    <measurement group_id="O5" value="63.8" lower_limit="48.5" upper_limit="77.3"/>
                    <measurement group_id="O6" value="68.1" lower_limit="57.7" upper_limit="77.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</title>
        <time_frame>Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Each of the 4 Primary Test Strains</title>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="97"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="4.3" lower_limit="0.5" upper_limit="14.8"/>
                    <measurement group_id="O5" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O6" value="4.1" lower_limit="1.1" upper_limit="10.2"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O6" value="3.1" lower_limit="0.6" upper_limit="8.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB80 [A22] - 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                    <measurement group_id="O6" value="3.1" lower_limit="0.6" upper_limit="8.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="4.1" lower_limit="0.5" upper_limit="14.0"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.4"/>
                    <measurement group_id="O7" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.0" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.1" upper_limit="10.9"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="41.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="41.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="41.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="14.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 [A22] - 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                    <measurement group_id="O3" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O4" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O5" value="86.0" lower_limit="73.3" upper_limit="94.2"/>
                    <measurement group_id="O6" value="75.8" lower_limit="65.9" upper_limit="84.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 [A22] - 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                    <measurement group_id="O3" value="78.9" lower_limit="54.4" upper_limit="93.9"/>
                    <measurement group_id="O4" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O5" value="86.0" lower_limit="73.3" upper_limit="94.2"/>
                    <measurement group_id="O6" value="75.8" lower_limit="65.9" upper_limit="84.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 [A22] - 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="44.4" upper_limit="97.5"/>
                    <measurement group_id="O2" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O3" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O4" value="51.1" lower_limit="35.8" upper_limit="66.3"/>
                    <measurement group_id="O5" value="66.0" lower_limit="51.2" upper_limit="78.8"/>
                    <measurement group_id="O6" value="58.9" lower_limit="48.4" upper_limit="68.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 [A22] - 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="18.7" upper_limit="81.3"/>
                    <measurement group_id="O2" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                    <measurement group_id="O3" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O4" value="28.9" lower_limit="16.4" upper_limit="44.3"/>
                    <measurement group_id="O5" value="40.0" lower_limit="26.4" upper_limit="54.8"/>
                    <measurement group_id="O6" value="34.7" lower_limit="25.3" upper_limit="45.2"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 [A22] - 1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O2" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                    <measurement group_id="O3" value="21.1" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O4" value="11.1" lower_limit="3.7" upper_limit="24.1"/>
                    <measurement group_id="O5" value="16.0" lower_limit="7.2" upper_limit="29.1"/>
                    <measurement group_id="O6" value="13.7" lower_limit="7.5" upper_limit="22.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56]- 1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56]- 1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 [A56]- 1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="95.7" lower_limit="85.5" upper_limit="99.5"/>
                    <measurement group_id="O5" value="95.8" lower_limit="85.7" upper_limit="99.5"/>
                    <measurement group_id="O6" value="95.8" lower_limit="89.6" upper_limit="98.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2:PMB2001 [A56]- 1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O3" value="84.2" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O4" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O5" value="85.4" lower_limit="72.2" upper_limit="93.9"/>
                    <measurement group_id="O6" value="86.3" lower_limit="77.7" upper_limit="92.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2:PMB2001 [A56]-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="18.7" upper_limit="81.3"/>
                    <measurement group_id="O3" value="47.4" lower_limit="24.4" upper_limit="71.1"/>
                    <measurement group_id="O4" value="59.6" lower_limit="44.3" upper_limit="73.6"/>
                    <measurement group_id="O5" value="54.2" lower_limit="39.2" upper_limit="68.8"/>
                    <measurement group_id="O6" value="56.8" lower_limit="46.3" upper_limit="67.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O2" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O3" value="57.9" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O4" value="28.6" lower_limit="15.7" upper_limit="44.6"/>
                    <measurement group_id="O5" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                    <measurement group_id="O6" value="36.0" lower_limit="26.0" upper_limit="47.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O3" value="47.4" lower_limit="24.4" upper_limit="71.7"/>
                    <measurement group_id="O4" value="21.4" lower_limit="10.3" upper_limit="36.8"/>
                    <measurement group_id="O5" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                    <measurement group_id="O6" value="32.6" lower_limit="22.8" upper_limit="43.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="0.3" upper_limit="44.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O4" value="9.5" lower_limit="2.7" upper_limit="22.6"/>
                    <measurement group_id="O5" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                    <measurement group_id="O6" value="14.0" lower_limit="7.4" upper_limit="23.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.1" upper_limit="12.6"/>
                    <measurement group_id="O5" value="4.5" lower_limit="0.6" upper_limit="15.5"/>
                    <measurement group_id="O6" value="3.5" lower_limit="0.7" upper_limit="9.9"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.1" upper_limit="12.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="1.2" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O3" value="73.7" lower_limit="48.8" upper_limit="90.9"/>
                    <measurement group_id="O4" value="72.3" lower_limit="57.4" upper_limit="84.4"/>
                    <measurement group_id="O5" value="63.8" lower_limit="48.5" upper_limit="77.3"/>
                    <measurement group_id="O6" value="68.1" lower_limit="57.7" upper_limit="77.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="72.3" lower_limit="57.4" upper_limit="84.4"/>
                    <measurement group_id="O5" value="61.7" lower_limit="46.4" upper_limit="75.5"/>
                    <measurement group_id="O6" value="67.0" lower_limit="56.6" upper_limit="76.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O2" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O3" value="57.9" lower_limit="33.5" upper_limit="79.7"/>
                    <measurement group_id="O4" value="61.7" lower_limit="46.4" upper_limit="75.5"/>
                    <measurement group_id="O5" value="51.1" lower_limit="36.1" upper_limit="65.9"/>
                    <measurement group_id="O6" value="56.4" lower_limit="45.8" upper_limit="66.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O2" value="30.0" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O3" value="31.6" lower_limit="12.6" upper_limit="56.6"/>
                    <measurement group_id="O4" value="27.7" lower_limit="15.6" upper_limit="42.6"/>
                    <measurement group_id="O5" value="21.3" lower_limit="10.7" upper_limit="35.7"/>
                    <measurement group_id="O6" value="24.5" lower_limit="16.2" upper_limit="34.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0.3" upper_limit="44.5"/>
                    <measurement group_id="O3" value="10.5" lower_limit="1.3" upper_limit="33.1"/>
                    <measurement group_id="O4" value="10.6" lower_limit="3.5" upper_limit="23.1"/>
                    <measurement group_id="O5" value="10.6" lower_limit="3.5" upper_limit="23.1"/>
                    <measurement group_id="O6" value="10.6" lower_limit="5.2" upper_limit="18.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="90.0" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O4" value="91.1" lower_limit="78.8" upper_limit="97.5"/>
                    <measurement group_id="O5" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O6" value="89.6" lower_limit="81.7" upper_limit="94.9"/>
                    <measurement group_id="O7" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O8" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O9" value="6.7" lower_limit="1.8" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)-1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="90.0" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O4" value="91.1" lower_limit="78.8" upper_limit="97.5"/>
                    <measurement group_id="O5" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O6" value="89.6" lower_limit="81.7" upper_limit="94.9"/>
                    <measurement group_id="O7" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O8" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O9" value="6.7" lower_limit="1.8" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O3" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O4" value="82.2" lower_limit="67.9" upper_limit="92.0"/>
                    <measurement group_id="O5" value="86.3" lower_limit="73.7" upper_limit="94.3"/>
                    <measurement group_id="O6" value="84.4" lower_limit="75.5" upper_limit="91.0"/>
                    <measurement group_id="O7" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O9" value="3.3" lower_limit="0.4" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                    <measurement group_id="O2" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O3" value="70.0" lower_limit="45.7" upper_limit="88.1"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.3" upper_limit="74.3"/>
                    <measurement group_id="O5" value="72.5" lower_limit="58.3" upper_limit="84.1"/>
                    <measurement group_id="O6" value="66.7" lower_limit="56.3" upper_limit="76.0"/>
                    <measurement group_id="O7" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O2" value="54.5" lower_limit="23.4" upper_limit="83.3"/>
                    <measurement group_id="O3" value="50.0" lower_limit="27.2" upper_limit="72.8"/>
                    <measurement group_id="O4" value="37.8" lower_limit="23.8" upper_limit="53.5"/>
                    <measurement group_id="O5" value="49.0" lower_limit="34.8" upper_limit="63.4"/>
                    <measurement group_id="O6" value="43.8" lower_limit="33.6" upper_limit="54.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="92.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O8" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O9" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="82.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.9" lower_limit="88.7" upper_limit="99.9"/>
                    <measurement group_id="O5" value="100.0" lower_limit="92.6" upper_limit="100.0"/>
                    <measurement group_id="O6" value="98.9" lower_limit="94.3" upper_limit="100.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="7.2"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.9" lower_limit="88.7" upper_limit="99.9"/>
                    <measurement group_id="O5" value="93.8" lower_limit="82.8" upper_limit="98.7"/>
                    <measurement group_id="O6" value="95.8" lower_limit="89.6" upper_limit="98.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O9" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="44.4" upper_limit="97.5"/>
                    <measurement group_id="O3" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O4" value="93.6" lower_limit="82.5" upper_limit="98.7"/>
                    <measurement group_id="O5" value="85.4" lower_limit="72.2" upper_limit="93.9"/>
                    <measurement group_id="O6" value="89.5" lower_limit="81.5" upper_limit="94.8"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O2" value="80.0" lower_limit="44.4" upper_limit="97.5"/>
                    <measurement group_id="O3" value="68.4" lower_limit="43.4" upper_limit="87.4"/>
                    <measurement group_id="O4" value="89.4" lower_limit="76.9" upper_limit="96.5"/>
                    <measurement group_id="O5" value="77.1" lower_limit="62.7" upper_limit="88.0"/>
                    <measurement group_id="O6" value="83.2" lower_limit="74.1" upper_limit="90.1"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2948 (B24)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O3" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O4" value="71.1" lower_limit="55.7" upper_limit="83.6"/>
                    <measurement group_id="O5" value="72.0" lower_limit="57.5" upper_limit="83.8"/>
                    <measurement group_id="O6" value="71.6" lower_limit="61.4" upper_limit="80.4"/>
                    <measurement group_id="O7" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O8" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O9" value="5.0" lower_limit="1.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2948 (B24)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="63.6" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O3" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O4" value="66.7" lower_limit="51.0" upper_limit="80.0"/>
                    <measurement group_id="O5" value="68.0" lower_limit="53.3" upper_limit="80.5"/>
                    <measurement group_id="O6" value="67.4" lower_limit="57.0" upper_limit="76.6"/>
                    <measurement group_id="O7" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O8" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O9" value="5.0" lower_limit="1.0" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2948 (B24)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O2" value="36.4" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O3" value="40.0" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O4" value="37.8" lower_limit="23.8" upper_limit="53.5"/>
                    <measurement group_id="O5" value="34.0" lower_limit="21.2" upper_limit="48.8"/>
                    <measurement group_id="O6" value="35.8" lower_limit="26.2" upper_limit="46.3"/>
                    <measurement group_id="O7" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2948 (B24)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O2" value="18.2" lower_limit="2.3" upper_limit="51.8"/>
                    <measurement group_id="O3" value="15.0" lower_limit="3.2" upper_limit="37.9"/>
                    <measurement group_id="O4" value="17.8" lower_limit="8.0" upper_limit="32.1"/>
                    <measurement group_id="O5" value="10.0" lower_limit="3.3" upper_limit="21.8"/>
                    <measurement group_id="O6" value="13.7" lower_limit="7.5" upper_limit="22.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2948 (B24)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.2" upper_limit="41.3"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0.1" upper_limit="24.9"/>
                    <measurement group_id="O4" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O5" value="2.0" lower_limit="0.1" upper_limit="10.6"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.3" upper_limit="7.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2707 (B44)-1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O4" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O5" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O6" value="87.2" lower_limit="78.8" upper_limit="93.2"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2707 (B44)-1:16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="84.2" lower_limit="60.4" upper_limit="96.6"/>
                    <measurement group_id="O4" value="87.2" lower_limit="74.3" upper_limit="95.2"/>
                    <measurement group_id="O5" value="85.1" lower_limit="71.7" upper_limit="93.8"/>
                    <measurement group_id="O6" value="86.2" lower_limit="77.5" upper_limit="92.4"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2707 (B44)-1:32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O2" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O3" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                    <measurement group_id="O4" value="74.5" lower_limit="59.7" upper_limit="86.1"/>
                    <measurement group_id="O5" value="78.7" lower_limit="64.3" upper_limit="89.3"/>
                    <measurement group_id="O6" value="76.6" lower_limit="66.7" upper_limit="84.7"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2707 (B44)-1:64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O2" value="30.0" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O3" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O4" value="57.4" lower_limit="42.2" upper_limit="71.7"/>
                    <measurement group_id="O5" value="59.6" lower_limit="44.3" upper_limit="73.6"/>
                    <measurement group_id="O6" value="58.5" lower_limit="47.9" upper_limit="68.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3:PMB2707 (B44)-1:128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O3" value="21.1" lower_limit="6.1" upper_limit="45.6"/>
                    <measurement group_id="O4" value="29.8" lower_limit="17.3" upper_limit="44.9"/>
                    <measurement group_id="O5" value="34.0" lower_limit="20.9" upper_limit="49.3"/>
                    <measurement group_id="O6" value="31.9" lower_limit="22.7" upper_limit="42.3"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O8" value="0.0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</title>
        <time_frame>Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3)</time_frame>
        <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;18 Months)</title>
            <description>Participants from &gt;=12 months to &lt;18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: HAV/Saline (&gt;=18 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=18 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
            <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains</title>
          <population>Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="97"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1:PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O2" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O3" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O4" value="8.5" lower_limit="7.5" upper_limit="9.6"/>
                    <measurement group_id="O5" value="8.3" lower_limit="7.8" upper_limit="8.9"/>
                    <measurement group_id="O6" value="8.4" lower_limit="7.9" upper_limit="9.0"/>
                    <measurement group_id="O7" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="8.2" lower_limit="7.8" upper_limit="8.6"/>
                    <measurement group_id="O9" value="8.1" lower_limit="7.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O2" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O3" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O4" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O5" value="4.2" lower_limit="3.8" upper_limit="4.5"/>
                    <measurement group_id="O6" value="4.1" lower_limit="3.9" upper_limit="4.3"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O9" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="97"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O2" value="4.8" lower_limit="3.2" upper_limit="7.4"/>
                    <measurement group_id="O3" value="4.4" lower_limit="3.6" upper_limit="5.4"/>
                    <measurement group_id="O4" value="4.1" lower_limit="3.9" upper_limit="4.4"/>
                    <measurement group_id="O5" value="4.1" lower_limit="3.9" upper_limit="4.3"/>
                    <measurement group_id="O6" value="4.1" lower_limit="4.0" upper_limit="4.3"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.4" lower_limit="3.6" upper_limit="5.3"/>
                    <measurement group_id="O9" value="4.2" lower_limit="3.8" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O2" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O3" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O4" value="4.1" lower_limit="3.9" upper_limit="4.2"/>
                    <measurement group_id="O5" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O6" value="4.0" lower_limit="4.0" upper_limit="4.1"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O9" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="22.6" upper_limit="79.1"/>
                    <measurement group_id="O2" value="23.5" lower_limit="10.1" upper_limit="54.9"/>
                    <measurement group_id="O3" value="32.0" lower_limit="19.7" upper_limit="52.0"/>
                    <measurement group_id="O4" value="24.6" lower_limit="17.8" upper_limit="34.2"/>
                    <measurement group_id="O5" value="36.8" lower_limit="26.9" upper_limit="50.3"/>
                    <measurement group_id="O6" value="30.4" lower_limit="24.3" upper_limit="38.1"/>
                    <measurement group_id="O7" value="8.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="8.6" lower_limit="7.4" upper_limit="10.0"/>
                    <measurement group_id="O9" value="8.3" lower_limit="7.7" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.6" lower_limit="64.0" upper_limit="161.2"/>
                    <measurement group_id="O2" value="68.6" lower_limit="28.2" upper_limit="166.8"/>
                    <measurement group_id="O3" value="82.6" lower_limit="51.4" upper_limit="129.9"/>
                    <measurement group_id="O4" value="117.2" lower_limit="89.7" upper_limit="153.0"/>
                    <measurement group_id="O5" value="104.6" lower_limit="80.4" upper_limit="136.0"/>
                    <measurement group_id="O6" value="110.6" lower_limit="92.0" upper_limit="133.0"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O9" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="86"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="6.2" upper_limit="18.0"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.1" upper_limit="11.5"/>
                    <measurement group_id="O3" value="8.6" lower_limit="6.1" upper_limit="12.2"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4.7" upper_limit="7.8"/>
                    <measurement group_id="O5" value="8.5" lower_limit="6.4" upper_limit="11.3"/>
                    <measurement group_id="O6" value="7.2" lower_limit="5.9" upper_limit="8.7"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.3" lower_limit="3.7" upper_limit="5.0"/>
                    <measurement group_id="O9" value="4.1" lower_limit="3.9" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="9.3" upper_limit="59.4"/>
                    <measurement group_id="O2" value="21.1" lower_limit="6.5" upper_limit="68.3"/>
                    <measurement group_id="O3" value="22.2" lower_limit="11.2" upper_limit="43.9"/>
                    <measurement group_id="O4" value="22.1" lower_limit="15.5" upper_limit="31.6"/>
                    <measurement group_id="O5" value="17.0" lower_limit="11.8" upper_limit="24.4"/>
                    <measurement group_id="O6" value="19.4" lower_limit="15.1" upper_limit="24.9"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O9" value="40">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" lower_limit="30.9" upper_limit="210.7"/>
                    <measurement group_id="O2" value="82.3" lower_limit="36.5" upper_limit="185.8"/>
                    <measurement group_id="O3" value="81.6" lower_limit="46.6" upper_limit="142.8"/>
                    <measurement group_id="O4" value="63.0" lower_limit="44.5" upper_limit="89.3"/>
                    <measurement group_id="O5" value="71.4" lower_limit="52.7" upper_limit="96.6"/>
                    <measurement group_id="O6" value="67.3" lower_limit="53.7" upper_limit="84.3"/>
                    <measurement group_id="O7" value="8.6" lower_limit="7.5" upper_limit="9.8"/>
                    <measurement group_id="O8" value="8.6" lower_limit="7.7" upper_limit="9.6"/>
                    <measurement group_id="O9" value="8.6" lower_limit="7.9" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" lower_limit="70.4" upper_limit="171.1"/>
                    <measurement group_id="O2" value="181.0" lower_limit="68.6" upper_limit="477.9"/>
                    <measurement group_id="O3" value="142.8" lower_limit="85.5" upper_limit="238.6"/>
                    <measurement group_id="O4" value="190.6" lower_limit="146.9" upper_limit="247.4"/>
                    <measurement group_id="O5" value="154.4" lower_limit="116.3" upper_limit="205.1"/>
                    <measurement group_id="O6" value="171.4" lower_limit="141.6" upper_limit="207.4"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.3" lower_limit="3.7" upper_limit="4.9"/>
                    <measurement group_id="O9" value="4.2" lower_limit="3.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="11.1" upper_limit="36.6"/>
                    <measurement group_id="O2" value="17.0" lower_limit="8.2" upper_limit="35.5"/>
                    <measurement group_id="O3" value="18.4" lower_limit="11.8" upper_limit="28.6"/>
                    <measurement group_id="O4" value="15.8" lower_limit="11.4" upper_limit="21.8"/>
                    <measurement group_id="O5" value="14.5" lower_limit="11.1" upper_limit="19.1"/>
                    <measurement group_id="O6" value="15.1" lower_limit="12.3" upper_limit="18.6"/>
                    <measurement group_id="O7" value="4.3" lower_limit="3.7" upper_limit="4.9"/>
                    <measurement group_id="O8" value="4.4" lower_limit="3.8" upper_limit="5.0"/>
                    <measurement group_id="O9" value="4.3" lower_limit="3.9" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="11.6" upper_limit="75.8"/>
                    <measurement group_id="O2" value="34.3" lower_limit="15.0" upper_limit="78.2"/>
                    <measurement group_id="O3" value="32.0" lower_limit="18.3" upper_limit="55.8"/>
                    <measurement group_id="O4" value="46.3" lower_limit="31.6" upper_limit="67.8"/>
                    <measurement group_id="O5" value="44.9" lower_limit="31.3" upper_limit="64.5"/>
                    <measurement group_id="O6" value="45.6" lower_limit="35.2" upper_limit="59.0"/>
                    <measurement group_id="O7" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O8" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                    <measurement group_id="O9" value="4.0">CI was not estimable due to the lack of variability of geometric means.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: Recorded from first vaccination through 6 months after third vaccination (Month 12). Participants recorded local reactions and systemic events in e-diary within 7 days after first, second and third vaccination. NSAEs: Recorded from first vaccination through 1 month after third vaccination (Month 7).</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the e-diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 60-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 120-µg Bivalent rLP2086 (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: HAV/Saline (&gt;=12 Months to &lt;24 Months)</title>
          <description>Participants from &gt;=12 months to &lt;24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Polydipsia psychogenic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anisometropia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site pain (tenderness at injection site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia (fever)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite (loss of appetite)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Somnolence (drowsiness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The data for the immunogenicity outcome measures at 6, 12, 24, 36 and 48 months after Vaccination 3 is not available at primary completion date and will be posted once the study completion date (last subject last visit) is achieved.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

